Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics (PLRX) announced that following a prespecified data review and recommendation by the trial’s independent Data Safety ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...

Explore Syndax Pharmaceuticals' Q4 2024 earnings highlights, including strong Revuforj launch revenue, label expansion plans, and a $2 billion ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The ...